Based on the Fulgent Genetics Inc stock forecast from 2 analysts, the average analyst target price for Fulgent Genetics Inc is USD 19.33 over the next 12 months. Fulgent Genetics Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Fulgent Genetics Inc is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, Fulgent Genetics Inc’s stock price was USD 17.66. Fulgent Genetics Inc’s stock price has changed by +0.23% over the past week, -5.00% over the past month and -19.25% over the last year.
No recent analyst target price found for Fulgent Genetics Inc
No recent average analyst rating found for Fulgent Genetics Inc
Company Overview Fulgent Genetics Inc
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California. Read Less
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology lab...Read More
Frequently Asked Questions About Fulgent Genetics Inc (FLGT) Stock
Based on ratings from 2 analysts Fulgent Genetics Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on FLGT's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for FLGT is USD 19.33 over the next 12 months. The maximum analyst target price is USD 22 while the minimum anlayst target price is USD 16.
FLGT stock's Price/Earning ratio is 7.49.
Our analysis grades FLGT stock's Price / Earning ratio at C+. This means that FLGT stock's Price/Earning ratio is above 22% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this FLGT may be undervalued for its sector.
The last closing price of FLGT's stock was USD 17.66.
The most recent market capitalization for FLGT is USD 0.53B.
Based on targets from 2 analysts, the average taret price for FLGT is projected at USD 19.33 over the next 12 months.
This means that FLGT's stock price may go up by +9.48% over the next 12 months.
We can't find any ETFs which contains Fulgent Genetics Inc's stock.
As per our most recent records Fulgent Genetics Inc has 1,313 Employees.
Fulgent Genetics Inc's registered address is 4399 Santa Anita Avenue, El Monte, CA, United States, 91731.
You can get more information about it from Fulgent Genetics Inc's website at https://www.fulgentgenetics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Fulgent Genetics Inc (FLGT) Stock
Based on ratings from 2 analysts Fulgent Genetics Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on FLGT's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for FLGT is USD 19.33 over the next 12 months. The maximum analyst target price is USD 22 while the minimum anlayst target price is USD 16.
FLGT stock's Price/Earning ratio is 7.49.
Our analysis grades FLGT stock's Price / Earning ratio at C+. This means that FLGT stock's Price/Earning ratio is above 22% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this FLGT may be undervalued for its sector.
The last closing price of FLGT's stock was USD 17.66.
The most recent market capitalization for FLGT is USD 0.53B.
Based on targets from 2 analysts, the average taret price for FLGT is projected at USD 19.33 over the next 12 months.
This means that FLGT's stock price may go up by +9.48% over the next 12 months.
We can't find any ETFs which contains Fulgent Genetics Inc's stock.
As per our most recent records Fulgent Genetics Inc has 1,313 Employees.
Fulgent Genetics Inc's registered address is 4399 Santa Anita Avenue, El Monte, CA, United States, 91731.
You can get more information about it from Fulgent Genetics Inc's website at https://www.fulgentgenetics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for FLGT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
